Impavido Capsule
NDC 69051-300
Product Information
Impavido (miltefosine) is a NDA-approved product labeled by Profounda, Inc.. Miltefosine is used to treat a certain infection called leishmaniasis. It is supplied as a red capsule for oral administration. This product entry covers the primary NDC 69051-300 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
Code Structure Chart
Product Details
What is NDC 69051-300?
What are the uses of this product?
What are Active Ingredients of this product?
- MILTEFOSINE 50 mg/1 - hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- MILTEFOSINE (UNII: 53EY29W7EC)
- MILTEFOSINE (UNII: 53EY29W7EC) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- SILICON DIOXIDE (UNII: ETJ7Z6XBU4)
- MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)
- LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)
- TALC (UNII: 7SEV7J4R1U)
- MAGNESIUM STEARATE (UNII: 70097M6I30)
- GELATIN, UNSPECIFIED (UNII: 2G86QN327L)
- TITANIUM DIOXIDE (UNII: 15FIX9V2JP)
- FERRIC OXIDE RED (UNII: 1K09F3G675)
- WATER (UNII: 059QF0KO0R)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 1494071 - miltefosine 50 MG Oral Capsule
- RxCUI: 1495070 - Impavido 50 MG Oral Capsule
- RxCUI: 1495070 - miltefosine 50 MG Oral Capsule [Impavido]
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.